Searched for
UCB PHARMA
Stocks in news: IRFC, Voltas, IDFC First Bank, Alembic Pharma, LupinMarkets declined sharply on Tuesday due to weak global cues, with the Nifty retesting crucial support near 25,400. Several stocks like IRFC...- Natco Pharma launches epilepsy treatment drug Brivaracetam in IndiaThe company has launched Brivaracetam tablets under brand BRECITA in India, Natco Pharma said in a regulatory filing.
- Merck's Indian unit MSD may sell primary care drugs to focus on core brandsA sizeable part of the divestiture is from the primary care segment with a few Indian drug makers showing interest. Valuation is, however, ...
- Pharmaceutical sector posts 12% growth in Feb: ReportDomestic companies grew at a modest pace of 14 per cent as against 19.4 per cent in the same period last year, and an average of 13.3 per c...
- Aurobindo gets USFDA nod for epilepsy, arthritis drugsLevetiracetam injection is used for treatment of partial onset seizures, myoclonic seizures in patients with juvenile myoclonic epilepsy, a...
- ChrysCapital exits Mankind, sells 11% stake to Capital International for $200 millionMankind has been growing at a compounded annual growth rate of 20% for the last five years, with revenues touching Rs 3,500 crore in year e...
- Cipla set to buy American business of Hetero Drugs for $550 millionPeople close to the transaction said Cipla will buy Invagen and Camber, Hetero’s wholly owned subsidiary, for about $550 million.
- Cipla ends 3% down even as company only Indian firm in race for Kremers UrbanIndia's third largest drug maker posted a net profit of Rs 294.58 crore for the corresponding period of the previous fiscal year.
- Cipla only Indian firm in race for Kremers UrbanIf Cipla is able to close it, the deal, pegged at around $1.3 billion, will eclipse Lupin’s recent $880 million buyout of Gavis Pharma.
- UCB files cases against Ranbaxy, Aurobindo, Glenmark, Sun Pharma, others on patent issueUCB alongwith others has filed separate cases against as many as 15 drug makers for allegedly infringing its patented drug Vimpat.
- Glenmark confirms patent challenge for its generic versions of VIMPAT in the US CourtGlenmark Generics Ltd confirms that it has filed ANDAs for Lacosamide tablets and oral solution with the US drug authorities with a Paragra...
- Lupin gets final US FDA nod for generic anti-epileptic drugLupin is the 5th largest generics player in the US (by prescriptions), the only Asian company to achieve that distinction.
- Glenmark US arm gets USFDA nod for anti-allergy tabletsPharma major Glenmark today said its US arm has received final approval from the US health regulator to market generic Levocetirizine Dihyd...
- Sun Pharma gets US regulator's nod for epilepsy drugDrug maker Sun Pharmaceutical Industries on Thursday said it has received the US health regulator's nod for marketing a generic version of ...
- StemCyte opens it first UCB stem cell bank of India at ApolloStemCyte Inc, USA, today announced the opening of it's first umblical cord blood(UCB) stem cell banking facility in India, at Apollo Hospit...
- Piramal denies takeover bid by GlaxoGlaxoSmithKline is in early stages of discussions to acquire Indian generic drug maker Piramal Healthcare for around $1.5 billion.
- Global Pharma looks to India for pain reliefWith the global pharma companies cutting back on costs, letting go of people and shutting down plants in large markets, the crisis is palpa...
- 'The future of biopharma in India is bright'One of the leaders in the Biopharma world, UCB is deep into research on very critical health issues. In a chat ,Charles-Antoine Janssen Man...
- Alembic signs licensing agreement with UCBAlembic today said it has signed $11 million licensing agreement with Belgium-based UCB for anti-epileptic drug Keppra.
- Pharma action hots up: UCB acquires Schwarz for $5.6bnUCB, the Belgian maker of the allergy drug Zyrtec, agreed to buy Schwarz Pharma for E4.4bn ($5.6bn) in cash and stock to gain new medicines...
Load More
